|Bid||174.05 x 1100|
|Ask||174.50 x 800|
|Day's Range||174.06 - 174.23|
|52 Week Range||89.62 - 176.19|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||59.22|
|Earnings Date||Jan 27, 2021 - Feb 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 02, 1998|
|1y Target Est||177.75|
Varian (NYSE: VAR) and the Cincinnati Children's/UC Health Proton Therapy Center today announce the start of the first clinical trial of FLASH therapy as part of the recently opened FAST-01 study (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases). The clinical trial involves the investigational use of Varian's ProBeam® particle accelerator modified to enable radiation therapy delivery at ultra-high dose rates (dose delivered in less than 1 second) and is being conducted at the Cincinnati Children's/UC Health Proton Therapy Center with John C. Breneman M.D., Medical Director of the center, serving as principal investigator.
Generation Investment Management releases quarterly portfolio
Varian (NYSE: VAR) today announced a new $10M investment and collaboration agreement with COTA, Inc., a Boston-based curator of clinical data in oncology. Both companies will work together to empower cancer clinics with data analytics and decision support tools, using real-world evidence to help guide clinical and operational decisions as well as drive more cost-effective care.